Pharsight

Sprycel patents expiration

SPRYCEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491725 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Mar, 2026

(1 year, 10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125875 BRISTOL MYERS SQUIBB Cyclic protein tyrosine kinase inhibitors
Apr, 2020

(4 years ago)

US7153856 BRISTOL MYERS SQUIBB Cyclic protein tyrosine kinase inhibitors
Apr, 2020

(4 years ago)

US6596746 BRISTOL MYERS SQUIBB Cyclic protein tyrosine kinase inhibitors
Jun, 2020

(3 years ago)

US7125875

(Pediatric)

BRISTOL MYERS SQUIBB Cyclic protein tyrosine kinase inhibitors
Oct, 2020

(3 years ago)

US7153856

(Pediatric)

BRISTOL MYERS SQUIBB Cyclic protein tyrosine kinase inhibitors
Oct, 2020

(3 years ago)

US6596746

(Pediatric)

BRISTOL MYERS SQUIBB Cyclic protein tyrosine kinase inhibitors
Dec, 2020

(3 years ago)

US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Feb, 2025

(8 months from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Aug, 2025

(1 year, 2 months from now)

US7491725

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Sep, 2026

(2 years from now)

Sprycel is owned by Bristol Myers Squibb.

Sprycel contains Dasatinib.

Sprycel has a total of 10 drug patents out of which 6 drug patents have expired.

Expired drug patents of Sprycel are:

  • US7125875
  • US7153856
  • US6596746
  • US7125875*PED
  • US7153856*PED
  • US6596746*PED

Sprycel was authorised for market use on 28 June, 2006.

Sprycel is available in tablet;oral dosage forms.

Sprycel can be used as a method for the treatment of cancer.

The generics of Sprycel are possible to be released after 28 September, 2026.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-225) Dec 21, 2025
Pediatric Exclusivity(PED) Jun 21, 2026
Orphan Drug Exclusivity(ODE-164) Nov 09, 2024
New Patient Population(NPP) Nov 09, 2020
New Indication(I-791) Dec 21, 2021
New Dosing Schedule(D-120) May 21, 2012
M(M-94) Oct 28, 2013
Orphan Drug Exclusivity(ODE) Jun 28, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DASATINIB ingredient

Market Authorisation Date: 28 June, 2006

Treatment: A method for the treatment of cancer

Dosage: TABLET;ORAL

How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage

SPRYCEL family patents

Family Patents